Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Pages: 147 Published: July 29, 2022 Report Code: GDME1407EPD

Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery. GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Drug Eluting Stents (DES) report provides key information and data related to:

Extensive coverage of the Drug Eluting Stents (DES) under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major Drug Eluting Stents (DES) pipeline products.

Review of Recent Developments in the segment / industry

The Drug Eluting Stents (DES) report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

Identify and understand important and diverse types of Drug Eluting Stents (DES) under development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

– Extensive coverage of the Drug Eluting Stents (DES) under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

– Identify and understand important and diverse types of Drug Eluting Stents (DES) under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Players

Abbott Vascular Inc

Adcomp Technologies Inc.

Advanced Bifurcation Systems Inc

Aeon Bioscience

B. Braun Melsungen AG

Biosensors International Group Ltd

Biotronik AG

Biotronik SE & Co KG

Boston Scientific Corp

Cardionovum GmbH

Cardiorev Pte Ltd (Inactive)

Columbia University

Concept Medical Inc

Cordis Corp

DISA Vascular (Pty) Ltd

Elixir Medical Corp

Envision Scientific Pvt Ltd

I.B.S. S.p.A.

InspireMD Inc

JW Medical Systems Ltd

Kaneka Corp

MangoGen Pharma Inc

Medinol Ltd

Medlogics Device Corp (Inactive)

Medtronic Plc

MicroPort Scientific Corp

MIV Therapeutics Inc

NuVascular Technologies Inc

Relisys Medical Devices Ltd

REVA Medical Inc

Sahajanand Medical Technologies Pvt Ltd

Shanghai BIOMAGIC Medical Device Co Ltd

Shanghai MicroPort Medical Group Co Ltd

Sino Medical Sciences Technology Inc

Stentys SA

Svelte Medical Systems Inc

Terumo Corp

Terumo Interventional Systems

TissueGen Inc

Translumina Therapeutics LLP

University of Strathclyde

VasoTech Inc.

Table of Contents

1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 12

2 Introduction 13

2.1 Drug Eluting Stents (DES) Overview 13

3 Products under Development 14

3.1 Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 14

3.2 Drug Eluting Stents (DES) – Pipeline Products by Territory 15

3.3 Drug Eluting Stents (DES) – Pipeline Products by Regulatory Path 17

3.4 Drug Eluting Stents (DES) – Pipeline Products by Estimated Approval Date 18

3.5 Drug Eluting Stents (DES) – Ongoing Clinical Trials 19

4 Drug Eluting Stents (DES) – Pipeline Products under Development by Companies 20

4.1 Drug Eluting Stents (DES) Companies – Pipeline Products by Stage of Development 20

4.2 Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 22

5 Drug Eluting Stents (DES) Companies and Product Overview 24

5.1 Abbott Vascular Inc Company Overview 24

5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 24

5.2 Adcomp Technologies Inc. Company Overview 30

5.2.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 30

5.3 Advanced Bifurcation Systems Inc Company Overview 31

5.3.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 31

5.4 Aeon Bioscience Company Overview 32

5.4.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 32

5.5 B. Braun Melsungen AG Company Overview 33

5.5.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 33

5.6 Biosensors International Group Ltd Company Overview 34

5.6.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

5.7 Biotronik AG Company Overview 40

5.7.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 40

5.8 Biotronik SE & Co KG Company Overview 41

5.8.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 41

5.9 Boston Scientific Corp Company Overview 42

5.9.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 42

5.10 Cardionovum GmbH Company Overview 47

5.10.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 47

5.11 Cardiorev Pte Ltd (Inactive) Company Overview 50

5.11.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 50

5.12 Columbia University Company Overview 51

5.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 51

5.13 Concept Medical Inc Company Overview 52

5.13.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52

5.14 Cordis Corp Company Overview 57

5.14.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 57

5.15 DISA Vascular (Pty) Ltd Company Overview 60

5.15.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview 60

5.16 Elixir Medical Corp Company Overview 61

5.16.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 61

5.17 Envision Scientific Pvt Ltd Company Overview 63

5.17.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.18 I.B.S. S.p.A. Company Overview 64

5.18.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview 64

5.19 InspireMD Inc Company Overview 65

5.19.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.20 JW Medical Systems Ltd Company Overview 66

5.20.1 JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview 66

5.21 Kaneka Corp Company Overview 69

5.21.1 Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview 69

5.22 MangoGen Pharma Inc Company Overview 70

5.22.1 MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.23 Medinol Ltd Company Overview 71

5.23.1 Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview 71

5.24 Medlogics Device Corp (Inactive) Company Overview 77

5.24.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 77

5.25 Medtronic Plc Company Overview 79

5.25.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 79

5.26 MicroPort Scientific Corp Company Overview 85

5.26.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 85

5.27 MIV Therapeutics Inc Company Overview 88

5.27.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 88

5.28 NuVascular Technologies Inc Company Overview 90

5.28.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90

5.29 Relisys Medical Devices Ltd Company Overview 91

5.29.1 Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 91

5.30 REVA Medical Inc Company Overview 92

5.30.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 92

5.31 Sahajanand Medical Technologies Pvt Ltd Company Overview 94

5.31.1 Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 94

5.32 Shanghai BIOMAGIC Medical Device Co Ltd Company Overview 98

5.32.1 Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 98

5.33 Shanghai MicroPort Medical Group Co Ltd Company Overview 99

5.33.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 99

5.34 Sino Medical Sciences Technology Inc Company Overview 104

5.34.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 104

5.35 Stentys SA Company Overview 109

5.35.1 Stentys SA Pipeline Products & Ongoing Clinical Trials Overview 109

5.36 Svelte Medical Systems Inc Company Overview 110

5.36.1 Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 110

5.37 Terumo Corp Company Overview 116

5.37.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview 116

5.38 Terumo Interventional Systems Company Overview 121

5.38.1 Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview 121

5.39 TissueGen Inc Company Overview 123

5.39.1 TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview 123

5.40 Translumina Therapeutics LLP Company Overview 124

5.40.1 Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview 124

5.41 University of Strathclyde Company Overview 126

5.41.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 126

5.42 VasoTech Inc. Company Overview 127

5.42.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 127

6 Drug Eluting Stents (DES)- Recent Developments 128

6.1 Jul 08, 2022: Cordis Names Bryan Loo President of Asia-pacific Region 128

6.2 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director 128

6.3 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results 129

6.4 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase 129

6.5 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022 129

6.6 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022 130

6.7 Feb 10, 2022: Contego Medical Announces Hiring of Steve MacKinnon, Chief Commercialization Officer 132

6.8 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference 132

6.9 Dec 09, 2021: Cordis appoints Dr. George Adams to Chief Medical Officer 133

6.10 Dec 08, 2021: Dr Jens von Lackum appointed to the Management Board of B. Braun SE 133

6.11 Dec 02, 2021: FDA: August 7, 2019 update: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality 134

6.12 Nov 18, 2021: MicroPort RehabTech TherMotion Cryo-Thermo compression device approved for marketing in China 135

6.13 Nov 08, 2021: Boston Scientific Announces Upcoming Conference Schedule 136

6.14 Nov 04, 2021: Terumo Corp Half Yearly Results For the Period 30 September 2021 136

6.15 Nov 02, 2021: Cordis Names Muscari President Of The Americas 136

6.16 Oct 27, 2021: Boston Scientific Announces Results For Third Quarter 2021 137

6.17 Oct 07, 2021: Construction begins on 280,000-square-meter MicroPort MegaFactory and global medical experience center 141

6.18 Sep 15, 2021: Opto Circuits Announces Unaudited Standalone Financial Results For The First Quarter Ended 30th June 2021 142

6.19 Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting 142

6.20 Aug 17, 2021: Opto Circuits (India) Announces Financial Results for the Year Ended 31st March 2021 142

6.21 Aug 17, 2021: Opto Circuits (India) Announces Board Changes 143

6.22 Aug 04, 2021: Terumo Revises its Full-Year Financial Guidance for FY2021 143

6.23 Aug 04, 2021: Terumo Corp. Announces Consolidated Financial Results for the First Quarter Ended June 30, 2021 143

7 Appendix 144

7.1 Methodology 144

7.2 About GlobalData 147

7.3 Contact Us 147

7.4 Disclaimer 147

List of Tables

Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 14

Drug Eluting Stents (DES) – Pipeline Products by Territory 15

Drug Eluting Stents (DES) – Pipeline Products by Regulatory Path 17

Drug Eluting Stents (DES) – Pipeline Products by Estimated Approval Date 18

Drug Eluting Stents (DES) – Ongoing Clinical Trials 19

Drug Eluting Stents (DES) Companies – Pipeline Products by Stage of Development 20

Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 22

Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 24

XIENCE BIOPRIME – Product Status 24

XIENCE BIOPRIME – Product Description 25

Xience Max – Product Status 25

Xience Max – Product Description 25

Xience SBA Everolimus Eluting Coronary Stent System – Product Status 26

Xience SBA Everolimus Eluting Coronary Stent System – Product Description 26

XIENCE Thinman DES – Product Status 26

XIENCE Thinman DES – Product Description 27

ZoMaxx Drug Eluting Coronary Stent System – Product Status 27

ZoMaxx Drug Eluting Coronary Stent System – Product Description 27

Abbott Vascular Inc – Ongoing Clinical Trials Overview 28

Xience SBA Everolimus Eluting Coronary Stent System – A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study 29

Xience SBA Everolimus Eluting Coronary Stent System – A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II 29

Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 30

Dual Drug Eluting Stent – Product Status 30

Dual Drug Eluting Stent – Product Description 30

Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 31

ABS Stenting System – Drug Eluting Stent – Product Status 31

ABS Stenting System – Drug Eluting Stent – Product Description 31

Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 32

Drug Eluting Stent – Product Status 32

Drug Eluting Stent – Product Description 32

B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 33

Coroflex DEBlue – Product Status 33

Coroflex DEBlue – Product Description 33

Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

BioFreedom Ultra – Product Status 34

BioFreedom Ultra – Product Description 34

Biosensors International Group Ltd – Ongoing Clinical Trials Overview 35

BioFreedom Ultra – A Pilot Study Registry of the BioFreedom BA9 Ultra Drug-Coated Coronary Stent for Patients With ST Elevation Myocardial Infarct (STEMI) Undergoing Percutaneous Coronary Intervention (PCI) 36

BioFreedom Ultra – A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding 36

BioFreedom Ultra – A Randomized Controlled Comparison Between One Versus More than Six Months of Dual Antiplatelet Therapy after Biolimus A9-eluting Stent Implantation 36

BioFreedom Ultra – A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding 37

BioFreedom Ultra – Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI) 37

BioFreedom Ultra – BioFreedom Ultra Stent in Hong Kong All Comers Registry 37

BioFreedom Ultra – Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy 38

BioFreedom Ultra – Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study 38

BioFreedom Ultra – Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice 38

BioFreedom Ultra – Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention 39

BioFreedom Ultra – Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction 39

Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 40

Coronary Stent System – Product Status 40

Coronary Stent System – Product Description 40

Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 41

ProGenic Pimecrolimus-eluting Coronary Stent System – Product Status 41

ProGenic Pimecrolimus-eluting Coronary Stent System – Product Description 41

Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 42

JACTAX Drug Eluting Stent – Product Status 42

JACTAX Drug Eluting Stent – Product Description 42

SYNERGY 48 Stent – Product Status 43

SYNERGY 48 Stent – Product Description 43

SYNERGY XD Stent – Product Status 43

SYNERGY XD Stent – Product Description 44

TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System – Product Status 44

TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System – Product Description 44

Boston Scientific Corp – Ongoing Clinical Trials Overview 45

SYNERGY XD Stent – Evaluation of Effectiveness and Safety of Synergy XD Stent in Routine Clinical Practice: A Multicenter, Prospective Observational Study 46

Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 47

DEBLIMUS – Product Status 47

DEBLIMUS – Product Description 47

PROTECT – Product Status 48

PROTECT – Product Description 48

ReNATURAL (M) – Product Status 48

ReNATURAL (M) – Product Description 49

ReNATURAL (P) – Product Status 49

ReNATURAL (P) – Product Description 49

Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 50

Peptide-Eluting Coronary Stent – Product Status 50

Peptide-Eluting Coronary Stent – Product Description 50

Columbia University Pipeline Products & Ongoing Clinical Trials Overview 51

C3 Exoenzyme Coated Stent – Product Status 51

C3 Exoenzyme Coated Stent – Product Description 51

Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52

Abluminus DES+ – Product Status 52

Abluminus DES+ – Product Description 52

Abluminus NP – Product Status 53

Abluminus NP – Product Description 53

Concept Medical Inc – Ongoing Clinical Trials Overview 54

Abluminus DES+ – A Multicenter, Prospective, Study to Evaluate the Safety and Effcacy of the Abluminus DES+ in an All-Comers Population 55

Abluminus DES+ – A Post Market Registry of Abluminus Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetes Mellitus 55

Abluminus DES+ – A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES for Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: an Investigator-initiated Pilot Study 55

Abluminus DES+ – ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) – First in Men 56

Abluminus DES+ – Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellitus Global – ABILITY Diabetes Global 56

Abluminus DES+ – Randomized Trial Investigating Clinical Outcomes of Two Sirolimus-Eluting Stents in Diabetes Mellitus 56

Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 57

Corio Pimecrolimus-Eluting Stent – Product Status 57

Corio Pimecrolimus-Eluting Stent – Product Description 57

Cypher Elite – Product Status 58

Cypher Elite – Product Description 58

NEVO Sirolimus-Eluting Coronary Stent – Product Status 58

NEVO Sirolimus-Eluting Coronary Stent – Product Description 59

Next Generation Coronary Stent – Product Status 59

Next Generation Coronary Stent – Product Description 59

DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview 60

Stellium Stent – Product Status 60

Stellium Stent – Product Description 60

Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 61

DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System – Product Status 61

DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System – Product Description 61

Myolimus Eluting Coronary Stent – Durable Polymer – Product Status 62

Myolimus Eluting Coronary Stent – Durable Polymer – Product Description 62

Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

Paclitaxel Eluting Stent – Product Status 63

Paclitaxel Eluting Stent – Product Description 63

I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview 64

Drug Eluting Stent – Product Status 64

Drug Eluting Stent – Product Description 64

InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 65

MGuard Drug Eluting Stent – Product Status 65

MGuard Drug Eluting Stent – Product Description 65

JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview 66

Excel II DES – Product Status 66

Excel II DES – Product Description 66

JW Medical Systems Ltd – Ongoing Clinical Trials Overview 67

Excel II DES – A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial) 68

Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview 69

MAHOROBA Stent – Product Status 69

MAHOROBA Stent – Product Description 69

MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 70

Gene-Delivering Stent – Product Status 70

Gene-Delivering Stent – Product Description 70

Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview 71

Elunir Elastomer Drug Eluting Stent – 38mm – Product Status 71

Elunir Elastomer Drug Eluting Stent – 38mm – Product Description 72

Elunir Elastomer Drug Eluting Stent – 44mm – Product Status 72

Elunir Elastomer Drug Eluting Stent – 44mm – Product Description 73

IoNIR Ridaforolimus-Eluting Coronary Stent System – Product Status 73

IoNIR Ridaforolimus-Eluting Coronary Stent System – Product Description 74

Medinol Ltd – Ongoing Clinical Trials Overview 75

IoNIR Ridaforolimus-Eluting Coronary Stent System – IonMAN Trial-First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System 76

Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 77

COBRA-Q Drug Eluting Stent – Product Status 77

COBRA-Q Drug Eluting Stent – Product Description 77

SYNERGY – Product Status 78

SYNERGY – Product Description 78

Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 79

Drug Filled Stent – Product Status 79

Drug Filled Stent – Product Description 80

Onyx Frontier DES – Product Status 80

Onyx Frontier DES – Product Description 80

Resolute Onyx DES – Bifurcation Lesions – Product Status 81

Resolute Onyx DES – Bifurcation Lesions – Product Description 81

Resolute Onyx DES – DAPT – Product Status 81

Resolute Onyx DES – DAPT – Product Description 82

Medtronic Plc – Ongoing Clinical Trials Overview 83

Resolute Onyx DES – Bifurcation Lesions – A Post-approval Study of the Medtronic Resolute Onyx Zotarolimus-eluting Coronary Stent System 84

MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 85

Fantasy Drug-Eluting Stent – Product Status 85

Fantasy Drug-Eluting Stent – Product Description 85

Firebird Pro+ – Product Status 86

Firebird Pro+ – Product Description 86

Firehawk Plus – Product Status 86

Firehawk Plus – Product Description 87

MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 88

Smart-2 DES – Product Status 88

Smart-2 DES – Product Description 88

Smart-3 DES – Product Status 89

Smart-3 DES – Product Description 89

NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90

NuSpun DE Stent Sheath – Product Status 90

NuSpun DE Stent Sheath – Product Description 90

Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 91

Corel + C Drug Eluting Stent – Product Status 91

Corel + C Drug Eluting Stent – Product Description 91

REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 92

ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold – Product Status 92

ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold – Product Description 92

ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold – Product Status 93

ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold – Product Description 93

Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 94

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Product Status 94

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Product Description 94

Sahajanand Medical Technologies Pvt Ltd – Ongoing Clinical Trials Overview 95

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – A Randomized Controlled Trial to Compare the Safety and Efficacy of Sirolimus-eluting Biodegradable Polymer Ultra-thin Stent (SUPRAFLEX Cruz) and Everolimus-eluting Biodegradable Polymer Stent (SYNERGY) in Treatment for Three-vessel Coronary Artery Disease: Multivessel Talent 96

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population 96

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Sirolimus-eluting Coronary Stent System in the Treatment of All-comer Patients with Coronary Artery Disease 96

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Post-market Registry to Evaluate the Safety and Efficacy of the the SUPRAFLEX CRUZ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-comer Patient Cohort with Coronary Artery Disease – The Cruz Senior Study 97

Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System – Ultrathin Drug Eluting Stents for Patients with Left-main, Bifurcation, Chronic Total Occlusion, or In-stent Restenosis Coronary Lesion in Real Life: The ULTRA a Multicenter Study 97

Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 98

BIOMAGIC Biroresorbable Coronary Stent – Product Status 98

BIOMAGIC Biroresorbable Coronary Stent – Product Description 98

Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 99

Firehawk Rapamycin Target Eluting Coronary Stent System – Product Status 99

Firehawk Rapamycin Target Eluting Coronary Stent System – Product Description 99

Shanghai MicroPort Medical Group Co Ltd – Ongoing Clinical Trials Overview 100

Firehawk Rapamycin Target Eluting Coronary Stent System – A Prospective Multi-center Open-label Controlled Trial of Comparison 3 Versus 12 Months of Dual Anti-platelet Therapy after Implantation of Firehawk Sirolimus Target- eluting Stent in Patients with Stable Coronary Artery Disease 101

Firehawk Rapamycin Target Eluting Coronary Stent System – A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk Stent System) for the Treatment of Atherosclerotic Lesion(s) 101

Firehawk Rapamycin Target Eluting Coronary Stent System – A Prospective, Multicenter, Single-arm Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in Patients with Coronary Artery Stenosis 101

Firehawk Rapamycin Target Eluting Coronary Stent System – A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography 102

Firehawk Rapamycin Target Eluting Coronary Stent System – Assessment of In-stent Intimal Repair and Vessel Reaction After Firehawk Sirolimus Eluting Stent Implantation of STEMI Subjects – An Optical Coherence Tomography (OCT) Study 102

Firehawk Rapamycin Target Eluting Coronary Stent System – Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice 102

Firehawk Rapamycin Target Eluting Coronary Stent System – Optical Coherence Tomography Compared with Intravascular Ultrasound or Quantitative Coronary Analysis to Guide Stent Implantation in the Treatment of Moderate-to-severe Calcified Lesion in Coronary Artery 103

Firehawk Rapamycin Target Eluting Coronary Stent System – The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of Firehawk Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: A Prospective, Multicenter, Single-group Study 103

Firehawk Rapamycin Target Eluting Coronary Stent System – The Safety and Effectiveness Evaluation of New Specifications (38mm) of Firehawk Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: A Prospective, Multicenter, Single-group Study 103

Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 104

BuMA Supreme DES – Product Status 104

BuMA Supreme DES – Product Description 105

Supreme HT Drug-Eluting Stent – Product Status 105

Supreme HT Drug-Eluting Stent – Product Description 105

Sino Medical Sciences Technology Inc – Ongoing Clinical Trials Overview 106

BuMA Supreme DES – A Prospective, Multicenter First-in-man Trial Program in China to Evaluate the Efficacy and Safety of Buma Supreme (Eg Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Subjects with De Novo Coronary Lesions, RCT Trial 107

BuMA Supreme DES – A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients with de Novo Coronary Lesions, OPC Trial 107

Supreme HT Drug-Eluting Stent – A Prospective, Multi-center, Single-group Target Value Post-marketing Clinical Study to Evaluate the Safety and Effectiveness of the HT Supreme Drug-eluting Stent System in the Treatment of "Real-world" Patients with Coronary Heart Disease 108

Supreme HT Drug-Eluting Stent – Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated with Unrestricted Use of the Healing-targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy after 1-month of Dual-antiplatelet Therapy 108

Stentys SA Pipeline Products & Ongoing Clinical Trials Overview 109

STENTYS Paclitaxel-Eluting Stent – Product Status 109

STENTYS Paclitaxel-Eluting Stent – Product Description 109

Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 110

DIRECT RX – Product Status 110

DIRECT RX – Product Description 111

SLENDER IDS – Product Status 111

SLENDER IDS – Product Description 112

Svelte Medical Systems Inc – Ongoing Clinical Trials Overview 113

SLENDER IDS – OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study 114

SLENDER IDS – The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study 114

DIRECT RX – OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study 115

DIRECT RX – The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study 115

Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview 116

ULTIMASTER NAGOMI – Product Status 116

ULTIMASTER NAGOMI – Product Description 116

Ultimaster Tansei – Product Status 117

Ultimaster Tansei – Product Description 117

Terumo Corp – Ongoing Clinical Trials Overview 118

Ultimaster Tansei – A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions 119

Ultimaster Tansei – Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population 119

Ultimaster Tansei – Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice 119

Ultimaster Tansei – Zotarolimus Eluting Stent Versus Sirolimus Eluting Stent in High Bleeding Risk Angioplasty 120

Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview 121

Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold – Product Status 121

Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold – Product Description 121

Next Ultimaster Metallic Drug Eluting Stent – Product Status 122

Next Ultimaster Metallic Drug Eluting Stent – Product Description 122

TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview 123

Cardiovascular Stent – Product Status 123

Cardiovascular Stent – Product Description 123

Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview 124

VIVO ISAR-Sirolimus Eluting Coronary Stent System – Product Status 124

VIVO ISAR-Sirolimus Eluting Coronary Stent System – Product Description 125

University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 126

Drug-Eluting Stent – Product Status 126

Drug-Eluting Stent – Product Description 126

VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 127

PowerStent Coro DES – Product Status 127

PowerStent Coro DES – Product Description 127

Glossary 146

List of Figures

Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 14

Drug Eluting Stents (DES) – Pipeline Products by Territory 15

Drug Eluting Stents (DES) – Pipeline Products by Regulatory Path 17

Drug Eluting Stents (DES) – Pipeline Products by Estimated Approval Date 18

Drug Eluting Stents (DES) – Ongoing Clinical Trials 19

Frequently Asked Questions

Request a Free Sample
$4000

Can be used by individual purchaser only

$12000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.